Call For More PET Tech Assessment Studies To Shape CMS Coverage Debate
This article was originally published in The Gray Sheet
Executive Summary
Preliminary evidence bodes well for positron emission tomography (PET) to be used as an adjunct in initially diagnosing cervical, ovarian, pancreatic, small-cell lung and testicular cancers, but further confirmatory studies are needed, according to AHRQ
You may also be interested in...
CMS Agrees With Industry: PET Coverage Process Should Be Overhauled
Medical imaging equipment manufacturers should play a more active role in the development of Medicare coverage policies for diagnostic imaging technologies, CMS Coverage & Analysis Director Steve Phurrough said May 7 at an AdvaMed meeting on Medicare policy in Baltimore
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.